Trials / Completed
CompletedNCT01729351
Qvar Therapy in Smoking Asthmatics
Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone and Chlorofluorocarbon Beclometasone in Smoking Asthma - a Retrospective, Real-life Observational Study in a UK Primary Care Asthma Population
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,195 (actual)
- Sponsor
- Research in Real-Life Ltd · Network
- Sex
- All
- Age
- 16 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the comparative effectiveness of extrafine hydrofluoroalkane beclometasone (EF HFA-BDP) and other inhaled corticosteroid (ICS) therapy commonly used in the UK, specifically fluticasone (FP) and non-extrafine (NEF) BDP (CFC-BDP and NEF HFA-BDP) in a UK primary care asthma population of current smokers.
Conditions
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2012-11-20
- Last updated
- 2012-11-20
Source: ClinicalTrials.gov record NCT01729351. Inclusion in this directory is not an endorsement.